Nebivolol does not protect against 5/6 ablation/infarction induced chronic kidney disease in rats - Comparison with angiotensin II receptor blockade

In conclusion, Nebivolol showed no benefit after 6 weeks in rapidly progressing, ANG II-dependent 5/6 A/I model of chronic kidney disease. This contrasts to the protection seen with 6 month treatment of Nebivolol in the slowly progressing 5/6 ablation model.